Chia Tai Tianqing

Chia Tai Tianqing Pharmaceutical Group is an innovative pharmaceutical group engaged in the R&D, production, and sales of pharmaceutical innovations and high-quality drugs. As a core enterprise of Sino Biopharmaceutical Limited (01177.HK), a Hong Kong-listed company, it is committed to providing patients with better health solutions and high-quality, affordable pharmaceutical resources. It is a nationally renowned R&D and production base for anti-tumor, liver disease, and respiratory drugs, recognized as a key national high-tech enterprise, a key backbone enterprise of the National Torch Plan Lianyungang New Medicine Industry Base, ranked 9th on the Top 100 Chinese Pharmaceutical Industry Enterprises list, and named the best industrial enterprise for pharmaceutical R&D product lines in China.

Chia Tai Tianqing has always regarded technological innovation as a pillar for sustainable development, with R&D investment accounting for approximately 20% of sales revenue in 2025, of which over 85% is allocated to innovative drug development. Leveraging its research institutes as innovation carriers, the company has successively established high-level R&D platforms such as the National Enterprise Technology Center, the National Postdoctoral Research Station, the Jiangsu Provincial Key Laboratory of Antiviral Drug Research, the Jiangsu Provincial Engineering Technology Research Center for New Liver Disease Drugs, the Jiangsu Provincial Engineering Technology Research Center for Crystal Form Drugs, and the Jiangsu Provincial Engineering Technology Research Center for Innovative Biological Products, continuously enhancing its R&D and innovation capabilities. Currently, the company has over 130 projects under development, including more than 100 innovative drugs, has undertaken 33 national major special projects, accumulated over 3,700 effective applications and patents, and holds more than 1,400 valid authorized patents, forming a sound pattern of "launching one generation, reserving one generation, and developing one generation."

Chia Tai Tianqing has established 5 major R&D and production bases in Nanjing, Lianyungang (Jiangsu Province), and Shanghai. Its formulation base obtained the first new version GMP certificate in China, and multiple production lines have passed EU cGMP and US FDA certifications, indicating that the company's drug production quality and management standards are at the forefront of the national pharmaceutical industry.

Guided by unmet clinical needs and supported by outstanding R&D innovation and manufacturing capabilities, Chia Tai Tianqing focuses on building product clusters in oncology, liver diseases, and respiratory diseases. In the liver disease field, the Class 1 innovative drug Magnesium Isoglycyrrhizinate Injection (Tianqing Ganmei®) won the 10th China Patent Gold Award; in the oncology field, the Class 1 innovative drug Anlotinib (Fukewei®) won the 23rd China Patent Award and set a record for Chinese innovative drugs selected for oral presentations at the 2025 ASCO conference. From 2024 to 2025, with the market launch of five Class 1 innovative drugs—Anlotinib Hydrochloride Capsules (Anbekit®)...